{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:04:37Z","timestamp":1758845077410,"version":"3.44.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The role of androgen receptor (AR) signaling in breast cancer is underexplored and may be particularly important in the treatment of patients with higher levels of circulating androgens. We discuss the management of a 70-year-old, postmenopausal transgender man with a six-and-one-half-year history of testosterone therapy, who presented with locoregionally advanced, invasive lobular carcinoma with apocrine features that was estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, human epidermal growth factor receptor 2 (HER2)-positive, and AR-positive. The approach to discontinue his testosterone indefinitely upon diagnosis was determined through shared-decision making with the patient. He received neoadjuvant HER2-directed chemotherapy and achieved a complete metabolic response. He underwent bilateral total mastectomies with left targeted axillary lymph node dissection. Final pathology showed a near complete pathologic response in the breast and a pathologic complete response in three sentinel lymph nodes. He completed a course of conventionally fractionated left chest wall and regional nodal proton beam irradiation and received adjuvant HER-2 directed therapy. He tolerated treatment well and remains disease-free two years since diagnosis. This case report and review underscore the importance of a multi-disciplinary and nuanced approach to personalized management of breast cancer in a gender-diverse patient population. Continued characterization of the AR as a potential therapeutic target in patients with breast cancer is warranted<\/jats:p>","DOI":"10.3389\/fonc.2025.1654048","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:16:52Z","timestamp":1758773812000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Androgen receptor-positive, locoregionally advanced breast cancer in a transgender man and an update on breast cancer management in a gender-diverse patient population"],"prefix":"10.3389","volume":"15","author":[{"given":"Yastira","family":"Ramdas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trenton","family":"Reinicke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn A.","family":"Schnurr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Nadeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Zakalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon W.","family":"Lahiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Brudvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayee","family":"Kiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Busuito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua T.","family":"Dilworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/or.2025.1564642","article-title":"Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action","volume":"19","author":"Kim","year":"2025","journal-title":"Oncol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2942-6","article-title":"Androgenic pathways in the progression of triple-negative breast carcinoma: a comparison between aggressive and non-aggressive subtypes","volume":"145","author":"McNamara","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-14-0243","article-title":"Complexities of androgen receptor signalling in breast cancer","volume":"21","author":"McNamara","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2009.159","article-title":"Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation","volume":"23","author":"Niemeier","year":"2010","journal-title":"Mod Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1118-z","article-title":"Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98","volume":"21","author":"Kensler","year":"2019","journal-title":"Breast Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq678","article-title":"Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers","volume":"22","author":"Park","year":"2011","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2523","article-title":"Human prostate cancer harbors the stem cell properties of bone marrow mesenchymal stem cells","volume":"17","author":"Zhau","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0979","article-title":"The prognostic role of androgen receptor in patients with early-stage breast cancer: A meta-analysis of clinical and gene expression data","volume":"23","author":"Bozovic-Spasojevic","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2564","article-title":"Combined androgen and estrogen receptor status in breast cancer: treatment prediction and prognosis in a population-based prospective cohort","volume":"21","author":"Elebro","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-010-0964-y","article-title":"Androgen receptor is frequently expressed in HER2-positive, ER\/PR-negative breast cancers","volume":"457","author":"Micello","year":"2010","journal-title":"Virchows Arch"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-008-0770-6","article-title":"Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers","volume":"13","author":"Ogawa","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12121","article-title":"Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation","volume":"104","author":"McNamara","year":"2013","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP8AVF8FDPTZLH","article-title":"Decreased androgen receptor expression is associated with distant metastases in patients with androgen receptor-expressing triple-negative breast carcinoma","volume":"138","author":"Sutton","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.steroids.2011.10.002","article-title":"Androgens and breast cancer","volume":"77","author":"Kotsopoulos","year":"2012","journal-title":"Steroids"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8162","article-title":"Male breast cancer: a population-based comparison with female breast cancer","volume":"28","author":"Anderson","year":"2010","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l1652","article-title":"Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands","volume":"365","author":"de Blok","year":"2019","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.11.007","article-title":"Interdisciplinary management of transgender individuals at risk for breast cancer: case reports and review of the literature","volume":"19","author":"Eismann","year":"2019","journal-title":"Clin Breast Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1097\/SAP.0000000000003321","article-title":"The impact of exogenous testosterone on breast cancer risk in transmasculine individuals","volume":"90","author":"Gurrala","year":"2023","journal-title":"Ann Plast Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1159\/000529859","article-title":"Invasive ductal carcinoma of the breast in a transgender man: A case report","volume":"16","author":"Heng","year":"2023","journal-title":"Case Rep Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000536212","article-title":"Complexities in adjuvant endocrine therapy for breast cancer in female-to-male transgender patients","volume":"17","author":"Sato","year":"2024","journal-title":"Case Rep Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.14.12723","article-title":"Breast cancer in male-to-female transsexuals: use of breast imaging for detection","volume":"203","author":"Maglione","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s40134-018-0260-1","article-title":"Breast imaging of transgender individuals: A review","volume":"6","author":"Sonnenblick","year":"2018","journal-title":"Curr Radiol Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jadohealth.2014.10.264","article-title":"Mental health of transgender youth in care at an adolescent urban community health center: a matched retrospective cohort study","volume":"56","author":"Reisner","year":"2015","journal-title":"J Adolesc Health"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13441","article-title":"Gender-affirming hormone therapy: An updated literature review with an eye on the future","volume":"291","author":"D\u2019hoore","year":"2022","journal-title":"J Intern Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.4.6","article-title":"Breast cancer in the transgender population","volume":"10","author":"Fehl","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241259466","article-title":"Breast and cervical cancer in transgender men: literature review and a case report","volume":"16","author":"Di Lisa","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2021.09.005","article-title":"ACR appropriateness criteria\u00ae Transgender breast cancer screening","volume":"18","author":"Brown","year":"2021","journal-title":"J Am Coll Radiol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacr.2024.02.019","article-title":"ACR appropriateness criteria\u00ae Female breast cancer screening: 2023 update","volume":"21","author":"Niell","year":"2024","journal-title":"J Am Coll Radiol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00266-024-03931-4","article-title":"Masculinizing mammoplasty for female-to-male transgenders: 10 years\u2019 Experience","volume":"48","author":"Huber","year":"2024","journal-title":"Aesthetic Plast Surg"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000007589","article-title":"Oncologic considerations for safe gender-affirming mastectomy: preoperative imaging, pathologic evaluation, counseling, and long-term screening","volume":"147","author":"Salibian","year":"2021","journal-title":"Plast Reconstr Surg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v14.i7.265","article-title":"Cancer screening and management in the transgender population: Review of literature and special considerations for gender affirmation surgery","volume":"14","author":"Panichella","year":"2023","journal-title":"World J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1097\/SAP.0000000000004052","article-title":"Nonbinary and transgender male patient preferences for gender-affirming top surgery","volume":"93","author":"Schafer","year":"2024","journal-title":"Ann Plast Surg"},{"key":"B35","doi-asserted-by":"publisher","first-page":"9226","DOI":"10.1038\/s41598-024-52396-7","article-title":"The wide base bipedicled (WIBB) flap in nipple-sparing skin-reducing mastectomy","volume":"14","author":"Cordova","year":"2024","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/7349633","article-title":"Flat aesthetic mastectomy closure with the angel wing technique to address lateral adiposity: technique and outcome analysis","volume":"2024","author":"Klenotic","year":"2024","journal-title":"Breast J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/1457496916645964","article-title":"Chest-wall contouring surgery in female-to-male transgender patients: a one-center retrospective analysis of applied surgical techniques and results","volume":"106","author":"K\u00e4\u00e4ri\u00e4inen","year":"2017","journal-title":"Scand J Surgery"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2012.08.003","article-title":"The goldilocks mastectomy","volume":"10","author":"Richardson","year":"2012","journal-title":"Int J Surg"},{"key":"B39","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/life14010138","article-title":"Breast reconstruction following mastectomy for breast cancer or prophylactic mastectomy: therapeutic options and results","volume":"14","author":"Simion","year":"2024","journal-title":"Life"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16836-y","article-title":"Effect of prepectoral versus subpectoral implant-based reconstruction on post-mastectomy radiation dosimetry","volume":"32","author":"Takayesu","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103782","article-title":"Postoperative complications of hypofractionated and conventional fractionated radiation therapy in patients with implant-based breast reconstruction: A systematic review and meta-analysis","volume":"77","author":"Park","year":"2024","journal-title":"Breast"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13040971","article-title":"Challenges in autologous breast reconstruction: A review of recommendations","volume":"13","author":"Sinik","year":"2024","journal-title":"J Clin Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2414859","article-title":"Omitting regional nodal irradiation after response to neoadjuvant chemotherapy","volume":"392","author":"Mamounas","year":"2025","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.01.023","article-title":"Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy","volume":"68","author":"McGuire","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.09.019","article-title":"Dose-sparing effect of deep inspiration breath hold technique on coronary artery and left ventricle segments in treatment of breast cancer","volume":"154","author":"Song","year":"2021","journal-title":"Radiother Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2024.100746","article-title":"Individual benefit in heart sparing during DIBH-supported left breast radiotherapy","volume":"46","author":"Ga\u00e1l","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.prro.2021.08.010","article-title":"Benefit of deep inspiratory breath hold for right breast cancer when regional lymph nodes are irradiated","volume":"12","author":"Peters","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.meddos.2024.03.002","article-title":"DIBH reduces right coronary artery and lung radiation dose in right breast cancer loco-regional radiotherapy","volume":"49","author":"Gough","year":"2024","journal-title":"Med Dosim"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2023.02.015","article-title":"Proton beam therapy in breast cancer patients: the UK PARABLE trial is recruiting","volume":"35","author":"Kirby","year":"2023","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctro.2021.01.012","article-title":"Selection criteria for early breast cancer patients in the DBCG proton trial - The randomised phase III trial strategy","volume":"27","author":"Stick","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.05.110","article-title":"Proton therapy for breast cancer: A consensus statement from the particle therapy cooperative group breast cancer subcommittee","volume":"111","author":"Mutter","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2018.01.017","article-title":"A dosimetric comparison of breast radiotherapy techniques to treat locoregional lymph nodes including the internal mammary chain","volume":"30","author":"Ranger","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2021.06.011","article-title":"What can proton beam therapy achieve for patients with pectus excavatum requiring left breast, axilla and internal mammary nodal radiotherapy","volume":"33","author":"Settatree","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.phro.2020.04.003","article-title":"Arms positioning in post-mastectomy proton radiation: Feasibility and development of a new arms down contouring atlas","volume":"14","author":"Depauw","year":"2020","journal-title":"Phys Imaging Radiat Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"290","DOI":"10.14338\/IJPT-22-00041.1","article-title":"Proton therapy for bilateral breast cancer maximizes normal-tissue sparing","volume":"9","author":"Brooks","year":"2023","journal-title":"Int J Part Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J Clin Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijrobp.2017.08.025","article-title":"Breast cancer biology: clinical implications for breast radiation therapy","volume":"100","author":"Horton","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2011.06.006","article-title":"Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management","volume":"11","author":"Shao","year":"2011","journal-title":"Clin Breast Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4875-y","article-title":"Breast cancer and its impact in male transsexuals","volume":"171","author":"Nikoli\u0107","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"B60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","article-title":"Treatment of HER2-positive breast cancer: current status and future perspectives","volume":"9","author":"Arteaga","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh336","article-title":"Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women","volume":"96","author":"Missmer","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj376","article-title":"Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women","volume":"98","author":"Eliassen","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0429","article-title":"Androgen excess in breast cancer development: implications for prevention and treatment","volume":"26","author":"Secreto","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2010.50","article-title":"EGFR and HER-2\/neu expression in invasive apocrine carcinoma of the breast","volume":"23","author":"Vranic","year":"2010","journal-title":"Mod Pathol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(89)90010-5","article-title":"Daunorubicin and vincristine binding to plasma membrane vesicles from daunorubicin-resistant and wild type Ehrlich ascites tumor cells","volume":"38","author":"Sehested","year":"1989","journal-title":"Biochem Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2023.103596","article-title":"Masculinizing hormone therapy effect on breast tissue: Changes in estrogen and androgen receptors in transgender female-to-male mastectomies","volume":"72","author":"Chaum","year":"2023","journal-title":"Breast"},{"key":"B67","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41379-020-00675-9","article-title":"Testosterone therapy and breast histopathological features in transgender individuals","volume":"34","author":"Baker","year":"2021","journal-title":"Mod Pathol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13058-024-01867-w","article-title":"Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals. medRxiv [Preprint]. 2024 Jan;10:2024.01.09.24300987. doi: 10.1101\/2024.01.09.24300987","volume":"26","author":"Heng","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2023.100121","article-title":"Toker cell hyperplasia in the nipple-areolar complex of transmasculine individuals","volume":"36","author":"Baker","year":"2023","journal-title":"Mod Pathol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.05.026","article-title":"Targeting androgen receptor in estrogen receptor-negative breast cancer","volume":"20","author":"Ni","year":"2011","journal-title":"Cancer Cell"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0799","article-title":"Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes","volume":"19","author":"Masuda","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"R87","DOI":"10.1530\/ERC-14-0543","article-title":"Targeting the androgen receptor in prostate and breast cancer: several new agents in development","volume":"22","author":"Proverbs-Singh","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9030021","article-title":"AR signaling in breast cancer","volume":"9","author":"Rahim","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Translational Breast Cancer Research Consortium (TBCRC 011). Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00004-4","article-title":"Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial","volume":"25","author":"Palmieri","year":"2024","journal-title":"Lancet Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-014-0427-8","article-title":"Targeting the androgen receptor in breast cancer","volume":"17","author":"Chia","year":"2015","journal-title":"Curr Oncol Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1707939","article-title":"Breast cancer in men","volume":"378","author":"Giordano","year":"2018","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.19.00792","article-title":"Management of male breast cancer: ASCO guideline summary","volume":"16","author":"Hassett","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.11.25323442","article-title":"Gender-affirming hormone therapy and impacts on quality of life: a narrative review","volume":"12","author":"Powell","year":"2025","journal-title":"medRxiv"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12131336","article-title":"The effects of gender-affirming hormone therapy on quality of life: the importance of research on youth","volume":"12","author":"Mazur","year":"2024","journal-title":"Healthcare (Basel)"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.12.056","article-title":"Changes in depression symptom profile with gender-affirming hormone use in transgender persons","volume":"348","author":"Morssinkhof","year":"2024","journal-title":"J Affect Disord"},{"key":"B83","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1089\/trgh.2020.0094","article-title":"The effect of gender-affirming hormones on gender dysphoria, quality of life, and psychological functioning in transgender individuals: A systematic review","volume":"8","author":"van Leerdam","year":"2023","journal-title":"Transgend Health"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06436-9","article-title":"Safety of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis","volume":"191","author":"Poggio","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000002200","article-title":"The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society\u201d Advisory Panel. The 2023 nonhormone therapy position statement of The North American Menopause Society","volume":"30","author":"Shufelt","year":"2023","journal-title":"Menopause"},{"key":"B87","doi-asserted-by":"publisher","first-page":"297","DOI":"10.52054\/FVVO.15.4.102","article-title":"Clinical guidelines for managing menopausal symptoms in women with (a history of) breast cancer","volume":"15","author":"Servayge","year":"2023","journal-title":"Facts Views Vis Obgyn"},{"key":"B88","unstructured":"Bone Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1654048\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:16:54Z","timestamp":1758773814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1654048\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":88,"alternative-id":["10.3389\/fonc.2025.1654048"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1654048","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1654048"}}